0001193125-12-335159.txt : 20120803 0001193125-12-335159.hdr.sgml : 20120803 20120803172502 ACCESSION NUMBER: 0001193125-12-335159 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20120803 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20120803 DATE AS OF CHANGE: 20120803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDIVATION, INC. CENTRAL INDEX KEY: 0001011835 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133863260 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32836 FILM NUMBER: 121007812 BUSINESS ADDRESS: STREET 1: 525 MARKET STREET STREET 2: 36TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94105 BUSINESS PHONE: 415-543-3470 MAIL ADDRESS: STREET 1: 525 MARKET STREET STREET 2: 36TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94105 FORMER COMPANY: FORMER CONFORMED NAME: ORION ACQUISITION CORP II DATE OF NAME CHANGE: 19960408 8-K 1 d391289d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 3, 2012

 

 

 

MEDIVATION, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-32836   13-3863260

(State or other jurisdiction of

incorporation)

 

(Commission

File No.)

 

(IRS Employer

Identification No.)

525 Market Street, 36th Floor

San Francisco, California 94105

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (415) 543-3470

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01. Other Events.

On August 3, 2012, Medivation, Inc. and Astellas Pharma Inc. issued a joint press release entitled “Medivation and Astellas Announce PDUFA Action Date for Enzalutamide NDA”. A copy of the joint press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

99.1   Press release, dated August 3, 2012, entitled “Medivation and Astellas Announce PDUFA Action Date for Enzalutamide NDA.”

 

-1-


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MEDIVATION, INC.
Dated: August 3, 2012   By:  

/s/ C. Patrick Machado

    C. Patrick Machado
    Chief Business Officer and Chief Financial Officer


EXHIBIT INDEX

 

99.1   Press release, dated August 3, 2012, entitled “Medivation and Astellas Announce PDUFA Action Date for Enzalutamide NDA.”
EX-99.1 2 d391289dex991.htm PRESS RELEASE Press Release

Exhibit 99.1

 

LOGO    LOGO
Medivation Contacts:    Astellas Contacts:
Patrick Machado    Jenny Kite
Chief Business & Financial Officer    Corporate Communications
(415) 829-4101    (847) 682-4530
Anne Bowdidge    Mike Beyer
Senior Director, Investor Relations    Sam Brown, Inc (media for both companies)
(650) 218-6900    (773) 463-4211

Medivation and Astellas Announce PDUFA Action Date for Enzalutamide NDA

San Francisco, CA and Tokyo – August 3, 2012 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action date of November 22, 2012 for the review of the investigational agent enzalutamide (formerly MDV3100) New Drug Application (NDA) for the potential treatment of men with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy. The companies announced on July 24, 2012 that the FDA accepted the enzalutamide NDA filing for review and granted Priority Review Designation.

About Enzalutamide

Enzalutamide is an oral, once-daily investigational agent that is an androgen receptor signaling inhibitor. Enzalutamide inhibits androgen receptor signaling in three distinct ways: it inhibits 1) testosterone binding to androgen receptors; 2) nuclear translocation of androgen receptors; and 3) DNA binding and activation by androgen receptors.

In the Phase 3 AFFIRM trial common side effects observed more frequently in enzalutamide as compared with placebo-treated patients included fatigue, diarrhea and hot flush. Seizure was reported in less than 1% of enzalutamide-treated patients. Serious adverse events, adverse events causing patients to stop treatment, and adverse events causing death all were lower in the enzalutamide group than in the placebo group.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at www.medivation.com.

About Astellas Pharma Inc.

Astellas Pharma Inc. is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. The organization is committed to becoming a global category leader in oncology, and has several oncology compounds in development in addition to enzalutamide. For more information on Astellas Pharma Inc., please visit our website at www.astellas.com/en.

GRAPHIC 3 g391289g54o01.jpg GRAPHIC begin 644 g391289g54o01.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`0P#(`P$1``(1`0,1`?_$`)\``0`!!`(#`0`````` M```````%!`8'"`,)`0(+"@$!``$%`0$!`0````````````$"`P0%!@<("0H0 M```&`@("`0,"!0('``````$"`P0%!@`'$0@2$Q0A%0DQ%B(R(S6V%W?P05&1 M0C,D$0`!!`$#`@8`!0,#!0$````!`!$"`P0A$@4Q!D%1(A,4!V%Q,B,(D205 M@5(SH4)B0S06_]H`#`,!``(1`Q$`/P#]_&$3")A$PB81,(F$3")A$PB81,(F M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB M81,(F$3")A$PB81,(F$3"+$>W'&]VD.1QHJ)U/.3J22YUHK:T[;JW&O5"@`M MT6\U4X&S.&'F("!CG9+@'(?3]X^BS[HS\\/XWMV&:,7>X'^FI]T5$/LNZZV^J"!%E M#"0R9K8Q/.44@$,'\RDHGR40'@/J`9=7-<;;,0]S;(R8;P8Z_F=/]79]'7`= M]_P'_DMV1ONJX6'-8$"?W.-NCD$CP(QY>UE%_(4%;A]:.TM6[#7[<[&K6VN6 M2NUR3BQHJE=EHR69OZLV!S%OIQ!W'++E=)R$ND"_F)A`$7*)0^G`CM(RA9$3 MKE&4/,$$?U"^/\_C>2XK)EA\ICWXV7"1$H6USKF""008S$2""".G4'R6Y7_' M_;Z#DK"3")A$PB81,(F$3"*"GYYO7T(Y=P@NN61G82!3*AZ_)-Q.2*$:@NI[ M#D#T(JK@8_')O$!X`1^F$4[A$PB81,(F$3")A$PB81,(F$3")A%:%^U_2-IT MZPZ]V/5(*[TBUQKB(L=6LL:VEH68CG)?%5N\9.TU$C\#P8AP`#I*%*<@E.4# M!1977;`UV@2@?`ZK<=O]P\YVIS./W#VUEY&#SF)8+*;Z9RKLKF.AC*)!_`CI M($QD""0OFP?DHZ^]>>NG=W8^F^ME[7NVN:_*-1D8]R8[S_3BSK*KJV/6!+(L MY,%K+4#$*G\H3`ND8XLUS*.FRRI_-N6%.%&^&-/?7`$`ER1+IM);5CX@$>?B MOZ3?HC[5^Q>\/XV5_9/V9@QP.Y?\?=97.+1^95&O^WS?9`'L?()!%>D9,+:Q M&JV$1G?I9TTN>T+_`$6S;"EKAJ/3,C9:^G8INO3$A4[Y9ZV\F&:<@C5#MC). M(]!TC]?G.R@D*8"9`BQ@`2VNWNU^1RA'*RIV8^$.D091G,`::!FCX.3N&NT# M0K\Q^\_Y-<+]64S^;Y/(YGE+#=R67?.ZV9`!G99(SG)H@1#R M)+1`B.@`&BGLE8"BY6;B()-FM,2+2-3D92-A&!G:Q$?FR\NZ391D:U*8?)=X M]`'VG8@J+DB?!@' MR$O'`Y3OAO\`:<>X`[/JWFW5OQ5XX^0*AD&$Q02V[:=K_FS?]57>U+V^GV)^ MX2"J"7F7VBD!@(*GKY\O`#"`<\<043,07B492.6E6J8 M+.8Q)ZV4D&R1O#Q579D5%RBF/L+P8Q0#^(/^N4[X;MCC>SL^K>;*X:+A4+C" M0I)828[7\GZ)(3$3$_'"4E(Z-%XKZ&@2#ULS^4O]/Z+?Y"J?O5_B#^$O(_7$ MIPB0)$`R+!SU/D/-*Z+K@33"4Q'JP);\VZ*N.H1,"BH'!`9>6C8L'2@I-AD7S5B#A4.!%)`7*J0+*`!@_A+R/UQ*<8`&9`!+!]-3 MT'YGR2JB^]Q1"*HV2$=Q!VNS^#^7Y_@@*I"J*`*IBL4@*&1`Y?:5,PB4J@I\^8$ M,8H@`\<"(9#AV\4VRV[V.QV?P?R?S7)DJE:6=^-C[IH_7R9K?6FOO;)V.W'* M,M0Z90:#ZD*]9+6@\-+;"F9$Q3-H2"UQ4F,A,JO7'#=)9HB0W(JE(;$SI9`Q MI0Q&.5(-%^@)TW$^`B-2=>C`$D`^U?0?;G97-?8-'*?9E\,?ZVX6N7(^?R-_G-]A?BEFNXS3S*J[,K<=*7*75&KI;N[HE!IS&=(G9J1C'+20D[?,%8'*T(1%\+-N@94@- MA.8RL*5@.F-MRW?JUUIME=1/M@E3D++(;`UG/6Y:-D]J5N-?V>NP[,MFU<4T'**#XWQ7ZJ*0J^1BE`814=O-J/95`ZGSE5KM@CXT_:Z+JAJ]:5Y)O/ M4MZYD;LYNM,<)E?F^$G&S#,R*()*']3=-,B1RI@!0E%E"35GKMVHMFG$S5\* MAK+3-/E*G3+<,Z^@9=:RR#UI-6E=@RD6IIQY#HMV\>D=T=8K0#G,F!5%3'R$ M4/.Z_M>L7W3NGVVZJWMVQ[+69S%2BR#U(\979#7VQWL+62K2E7TE.12";F6C4@I5E2(XB& MZS=VBXE@74*#4ATE"'7$@&*(".$5FU.)6IW9/KR\@JI:M<,-H5C;(V:-L.RY M*WS5X;0U:B)R'E+K#+2,O&LY^.>N@5^0FZ<*@=8R0F`I0#)1<^N'$KKC<-1I MV_JK*N+O9[Y>9#5O82`GW$I7MC!*-["]:TNULQ<`ZKCB.K+H46D8=$8_EBB= MOXBF)S/!%NILK^W5?_<77_\`E$=D(L&]]=C[`U#TR[*[,U6=PAL"F:CMLU6I M%JT*_*YWOWB>'YO7B\C.KA9%]N\$Z5[O#W)-6X8C=IJM%]G]"^ MF%!Z46G;M3395?8U)TQ);IJ_<]G9GI=UN+[&U`]NB=JR6VSOE)VQGLLPFDLY M9K+K1[]NX%J5#U&3(&MOXOCZL"676-N3&HS%PC M\-]E=^QNZ.R?5W?]!4>1':C6WXP:!V(94!9RI#UK9-EE=DPJ6U--6R,2`J#=GL. MOSC]@R4$"C$RPM'`<>@>,"0R,OFJ/A9MZ1ENF=]9B MZO`L[6[>[4YGM?D#&SLK+[OOP3UR]P&^F]CG@V=?K$X;HN?W7;]DL)I&?OC>ZKNODNV3]RZBWON*3XXI M%3(7?8W#<9CF%M=<3?`!K'.XEF<^UOL//GG\5GY4Z^-R19 M59A>W#X]$';VJJ90,:34VV,H"-D6?=N6U^ZLKQPX?VAMK*SV!_`I.7"JROH9 M$0.811X#6Y%EDJ8T%S33RE4($EWB)1+/U]!.S4DZ:EW792HQY\U/N"RJG&YC MEOK_`#LO+JK@(0%TJK8^]LZ0.1"$;C&(`$I&0#26_P#^19VXL+[J!H>>LNN[ MG^*XF5^)"8C/98;JJYY(KD")RQJIRLB\91B6F1Z0L,]C>O6CNFM^ZA;8ZKTZ M`T7L>S=H-1:(F*?K9L6OP>[]7[)D7$3?*OX._ M^+YS@^]<\3(QX@TV4V?J@+9R%,ZP=LQ/]+A6#J72FN.T< M5W)[`;OT=!]Q.PE=[(;HTW!:8V!.0;9EK"BZWN!:K2-:T=&ZKEJ>O1DZ<5*Q M.I/U(.95=\*IEC\I\8]>-'-IOS,S'&1R$+IQ$)$#:(R]$1N],?1(3W,YW.^H M6UYKN+D^SLG@.U^V^3GP/:EW$8V5/+IKL)OMR*=]U]WM`VWM<#3&&HJ$=HB` M"3R/F<':NCVD^[W6>@R.D+[T=:[9F:CK:U75[:/OFJ-6V>TT_>^@[E<3O9E: M;A;K"4IVO%O%#NS1TLW9+)"4I3\TQNAD<97S-$#7=B;_`$F1),($QL@9ZD@@ M/%W&X1)"C%GDXOV-R'USW=E1Y'C.Y#C0LOKJ%>S(R(5V86;541`0G5*V,9Q: M.ZN5@.K+=WHAJF?B:'-]D-JOFL[O[MHK!['Y,N'CN>+J/Q_EV_P#TY'KEJ[`CTP'D(18-YN7+ MKS?[(YO&R.1J[3X82K[7X,3QJ(D-*RP2/R,JP#_V9%H,S_M@(0`&U;W9LEYN MO42$$Q3B0HG(!@(<2@)B`?CS`IA#DH&\0YX_7C#>*ERS>"MI_3J[*66'MLG' MIR$W7FCMI7UW@BNC"?<#$&0>1K4_*#:1?)I)IJ.`+[O40"%,4HF`Q0KGPBPQ M9]!:WM=\#9$@RG&5I<0K>N3CB`M5CKS*V5]FLHX9PMMC8>29LK!'-55C^*;@ MA@$AA(;R3'QPBI(KKUKVN057KE34ME3C*6^EWM83@;A/(*1!9\BI9F.04=/' MGG$/U%S*BV4`Z2:P@=,"&*40(N27Z\ZMEZ97:(,/(Q]5.)U4WIW`&4,8_P!#&,(D51*Z M%UW-N*>[DD;0Y>4.16FZL\->;C\N/L#H'97EA5_;)S;Q)\JDHNZ%O=OG)V,C'C1*/ M6A"O9*8<>V!^`EZ09G*+<"F,;Q\S&.)%.0.CJ+`RL#+`6?FE:D^EI*FM+)8Y M:RO[=5_]Q=?_ M`.41V$5X3JD*E#2AK(:-"`,Q>,@@$,=05779959&VJ1C;$@@@D$$%P01J"#J"-05UQ5K\?'1U^Y2:1 M@W.:UG4;2QL#'KW-[JV:^Z^5NS&.SL$4JVTM-67]J)L$73A%RUCE6ZD2DMP" M;8HD\2ZN'"X5;#%QXYTX$,1+*%8LQEB4(9-Z,2=0;44@_*!'W$_]8G`G(9F_%I^6V:A M6:U$2_8]-A.;K-]T4DZU<$X=O*1BTFO6'3MY!-49+[RZ^XF;-R)OUUSF7`ZA MC"-%6#C4Y5N9"+7WMO/@=H8:=/'737Q6SY/O;N?F.)XWA>0RIV8/$B0Q>@G5 MN,3I8`+#MVQ$'D=@B!%@%@BB]"NF$!*4NW5N4N/")=MS*1C?U*,&8EY;(I@4OC9AQ6)&<)`6&-9>$3.9 MA$A^D-VWJ78@@$!F70Y?VSWAF8EU%LL..=DU2JORXXF/',NJD")0LR(UB9$@ M2)2#63<[YR=7QM;I9UFV3?I[9[F6K%AL:8TOO&\:;#:3%DQ31CD-@ M,J1989A9'+>*`$TGIDR2(-1`@./6!0!D<7BY%QR/W*\B6UY5SE`G:X#[2`=- M'9V`#Z!8W#?9W<_#<55PO]GF<;C2,L>&7C4Y7QI2.XRH-L)&'JUV.:WU,'4_ M8^G752?T;3NM[>MMJ=JC7UG@[?3H/7UYL%%F("W5N3?RL=8FELKD\PMAK`$T MX<.EWBCP[MR[$ZJRAU/(V59/&XN5C1Q)`QIC($;28D$:N"-7S8!$0$1&,0(@".BI(?IYU MEP;]L19-Q M%.6BC=XF"I3E5+Y9:JX?#JQK,67N64V$/[DY3.G1B2\2#J"&(+'J`K]WV5W7 M+FL;N'$LQL/E<2,HUSQ<;'QP8S_5&R%5<86QD"8D61D#$D,Q4!ICJ-U;UY=H MC=$=9KOM:\56/D(&AWK>.Z;QMUU0(9^W1:R;77A[[/R,;`(R;%RDBJ_:)"Z< MMCE(+DZ9Q`U[%X_'Q);J_Q[)8B"+MPW%^FB8J95@)X ME!E#Z@:`@)PWV1W'P_%U\)..%G<329&F MK,QJ21M/<.9W1#O+)O$NX*[ZK8V;*Q&,Z=OM-7&(K$8 M"$0(".U@S+.M*BJS6ZM7:C4%FQJ_4:]!UZ&;H2'W,[2%B8U".ADE79UEUUQ^ M`S*`*J&,97Q$PB(\CF377&JN-<-(1``_(:!:#+RK\[+MSONOK#(O9>8_<#V M3D5F2[]\>>=D7>*QY(HC0SGT^LBQ$`A6PD3,44R&3Y*4!$>2*W4.KNND)19X MFK-%CE8MG&EABND`02^$_)(D<).A;&=)',Y2()@3,F)_'Q.)B#XX17'3M#U. MC662L,"]ED4I"O.*Z2).JV.U9-WCLKUXX:KF;BY2<+N2`;DAB<\`!_,J:0)R MZ+C?===72(-!=Q3Y91DQC8])923<*JF;Q4,R@&H*BM["G.,9&-R&'CZF1`X< M&,<30BIT>M6ID?1XP;I3X[8&:7R)!=V!6_O2-2)245+A5B&D863)*QSE1_(',DY14C#-B*E%SZW3=JC%)HID5`X`B M=8@\@NMYD4NWTS1&UL<70C!T>;=*RZC@RSQ11LH6<"8"20,W$.!;+FGG1O#G MQ`R@#_XEX(H1]U[UW)#`?.)/O"U>,0AH%%W//GC>-B6JC-1JP1;.S+H"B@,> MB`"8IE#@F'F8X_7"+D:]?-8M%H]OE9#U)QE@3M#-+_[@<#X M)S)3*"/T,=-4R1A%("$(12DYI>E6`LB@^+-D92EC+;G,8TG'[>-_<8>DRDH1 MD50405760*J<@@*7NY.!0,8PB13=&UI4- GRAPHIC 4 g391289g56r44.jpg GRAPHIC begin 644 g391289g56r44.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`*@"@`P$1``(1`0,1`?_$`)P``0`!!`,!`0`````` M```````)`0,'"`0&"@4"`0$``@,!`0``````````````!@<"`P4!!!````8" M`@$"!`0#!P4``````@,$!08'`0@`$0D2$R$Q411!<3(S\"(588&Q(V,6"I&A M8E,7$0`"`0,#`@0$`PD``````````0(1`P0A$@4Q05%Q(@9A,A,'@4(4D:'! M4F*",R05_]H`#`,!``(1`Q$`/P#W\<`IWCOKO'?T[^/U^7Y8X!PG-T;&5O6N MSPXH6EK;4IRYQ0>6`XD\DP)I)Q)H,#+-*,!D0#"S`"QD( ML9SC.,]XYX9%S@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'Y]8>_3ZL=]=]=_A M]?[^8?4CNV?F\F>T=*]B-7R)V]LC2,AJ;LV"J]"R%.KS<-+ M-RUOBLLA4=4?YBUMD3)%WYXE+?DDO(E2^.D$9SZ#!!'LBE)TK3]G;6FO2O3L M<7G,C-PL/_HXBE<6.W.=I43NPVM-*3TCMK]2O=1:ZNA"/_R$I]9]U:6U+;D> MEDHB]"3^ZX3&ZYJQF,-;G*V$3W!YN^$36UD:48W$8E+ZU(TC!%,^D27'NJ'$ M`EIY25OTWKDX6O1UE.$:4=6I3BI4_LW?P*P^[O*9V7[&Q M`C`84,.0Y#G&,XSCKF^6W<]GRUT\BY;<9QMQC==;B23\Z:_O.S\Q,QP"V:<4 M0`1AQ@"BPA&,9A@L!``!8LA2G-#@91Y!F/@82:#.!`%CL(@YQG& M20`1AYI9)8,=C,-&$``8[QCL8Q9P$/>18^>?QX!<"((L8$'.,AS\LX^6>`5X M`X`X`X`X`X!YE-Q/"/"YELG,KO.NNU:VI:VEV7Z3IX00F?RZ?GJXPD#N[.Z% MU<"AYJ*0F8$>:K3!]4=6&"RH+_IPQ*4=X>U?O5R'MSVW#@XX.-?R[5:7KDM6 MJU4=OTWNI\J6Y-JM&I-$TXWW?/!PXXTL>W<[?)Y:]P7N-?%Y.7%SHG)V\C5;IQ3BG!ZU=:J7G5 MRY/+W/U:&)X/'9W)WXX/&V+V3F3>D+<7.6C3K1=DZ>K\OXLA]O@L;)N6XNU]6%BY. MY"+2FHRF^JCM].QR:MTI12:KJ91HS MFCT5%7LWJE(U8T[CE75].K,F"[#9$J[ATFG,G*K?K M!3J/CMW?T0:7:2R;7VG#$Q9@G>G*E:X\J5V!)"!Y2.:Y+_1$Y@DI;KD8'2=M MO*S*===Q6#1NBM)+@W#N1SH9)?SFV55.JWB!,8AQTJ=8EDI:&=JFI)TA4($X MQB"<''I6DA``0A9X!E&XO(^^ZV>.2<[][):M6-2KW!$P#G;6B2S6#N5AA4.% MBH*]CB#_`'3'3W.)`42/^I$N).`C-R6F-P$?1G80@:EL'G,<(;)*/QN;X_-I M-+:CV(DL7AU9[`SEXK&P:J%)9HF)71!!,%L$?U3S#2)"E.]0#%:;UE@"(8RP M@*/&4!O%(/(*QMODHC'C:9:T>Y#-7W6EYV2>[))DC2BC,/9T#VY1]OC#DQC2 M*'A2ZO#@F39`H",!)92P(LA%D&<"`XWC9\BD2\B596Q,&FN9/4$YH^\)I1%G MU1,7IG?9+&93#Q)<_>FKF5,C2&MCP6I'[&?:"+!B8X&<9R#.>`8,MOR05$SI M97LQ,GAY1Z+4G=<&H)EL"-H37)#?FQ4IL5LK5[E#>L)$!&90&OKVO-(/=A&X M0/,B2+3"A&`9TGWP&0]U-^=B-15TV?(IX]+:V$HBMJO.LV77U$;EI6&1=K;& M9L=GN6(P1J:/J>8KC(NR-83S#2$Y@5>3?00$8P]9`ZMH=Y*;YW@*K2>Y\>=M MTAK7:$(>)Y']C)G5Q1GQE80(S!ZWW"AF^V/TC]&!@9P\A_FNHC0 M2K-3KF*@DMV(@.V0G![AKG5SJT(UB6M6B)L$T=+'+:GI/]V[M:./2(@X2<'V MYI>>\&B+Z%D(&:-GO*)4-$USI+9=?,"[8*/[Y7K4E+4LI@C^U-:50GMM">Y- M\[4K'-,KP8T,:8LO"M&$K"P)IOMYP`8!AP!)L3Z_1_/GU9P(0>^NLY](LA[S M\,8^.<9^6.NN`:$[=Z?S?:AXB;0_W/($^O"!L5)K'UL9G%SKIGMQQ,49,3*9 MC;$/]^>&1A,FS[9S``O"!;G&!&B^'7.WP?,QX&S-X^/9N\@U2W>NISE:_JA% M^G>GK&;58O5=#JX/)K`5R[:M1>;)4C-I-0\:0::W>$JU57^&&AV97\/M`>AV MNC*U1-[@M=?_`'#8QBK`TA[7UE3;2C0LS)!H<)(0WN;A;MW+4Z=$A`I%E8W- M.5;AD03S6_!O,R\W,Y+)EE9EV5S(JBU64*Q;7@?5[>Y7C^5M1S%.[;Q9[H-Q^:$DZ-25=5%K5)ZK MHV1E._DN\@L;MQJ>XYXJKDK]SB3VAAEN1:'L]C2>%V'!F7)K>8RITC;6J:,C ME<>)#@<Q[<]N7;$[BSXRE*W6,I2C#8Z_,TY5ET:<>O==B0;S9*=DKH M\74_KO3RF;,L>T=HTM?UP".,K.-KDT&KRS M_$/NC7&[-64OIG)'FE-5=B]`J!UOW.V+BA:1&X1!AUY4%,,Q:80YA6A<6VUK MC2(528C(L@8;;/8&]=`O(5?M!"J6I*GH*1:=S8VJUZU=&HU'W"8.SC*FVW:Q>7".GO"Q< MG)2^\-,:HQD9A61%%F<`W2\OVKMO3#PVT-JKJ5KGL+,P2"Q=?#I94#A(3;#N MF$54TB<[.E[;84HE4H=%3W)FB0)4K:I.,T-N32/5J(7%6EG7E>FT;[731)P1.KBE)+9"JKKR"2^5N[J_NA*L6`JS M#"20&EDX&(HK!H^`;=ZPZY7@K\['D(VWL*K)?$J<1ZW49KSK_.I"2C`Q3E(E M31=^G"J)'`5*%JDAM?F`\!II@2NAJ MC_D\55=-]A-FV,)"7%/M"-([N-X(*\U,N9R#DRS#(H^UR'!QV%)HC1"`P1(<;_VY_QRK.I:?ZS7$DWD;J6% MJX=6:MJ0FS2PD3;(H["4L_93$CD)(X-[S5*C[Q2I$>'(ER95@6/EV!*E7M6S MG6OQ316H('"WEUMFI-$T4,C<'9$*8Z0NMI,-(A1%,#8CR?A,-V7SD.2PEB,P M7[HOB+T_S<`\]9_B@V^QX.O'%!J]K#[C:_4'8%LW&FVL,_7M#$*R'8N>SF0. M\"<%*I2!A(DJ1I?T8TZ=2?@!I8#B,&9.$6$0&W>X&V^]_D6UHG6DVO'BPVVH MNQ-C(V?6EJVSMPSQ6NJ-I:(R+[`:05QXI]S-?_`"CZ9ZWL,9F%B^+K6G9R MP-R:"LY8>2Y$4FGF<">EAU'RAS5N8E6`QZPF!*!`3]L+)WW_`-Z$8!K#P%@> MT'@%!?+/Y9_PX!Y/M(ZJVD>/,+Y395`(;(H16$]L625[)-BWAL/3-D:0-4JC MCJO;ZR$ZI#$DQL=S;40$K>(O!KJ4DTW/9KYUIWO8TD^ M-R-TY0;^2[5?XU_+*LG*O>BZ)$H^,=8QC'RQCK_I_9PE0[HZQ],<]!7K^/\` MO_CP!P!U_'\?GP!UCZ<`<`=?C^.>`.`.`.N`.`.L?3@#@%.L?3'RZ_N^GY<` MKUCZ<`<`MG?LF_J_:,_3^K].?T_^7TX!81_M!_8_6H_:^7[XOG_K?^[_`%>^ ?`